Socio-Economic Burden of Myocardial Infarction Among Cancer Patients.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 21 09 2020
revised: 31 10 2020
accepted: 03 11 2020
pubmed: 21 11 2020
medline: 16 3 2021
entrez: 20 11 2020
Statut: ppublish

Résumé

Cancer patients face a higher risk of future myocardial infarction (MI), even after completion of anticancer therapies. MI is a critical source of physical and financial stress in noncancer patients, but its impacts associated with cancer patients also saddled with the worry (stress) of potential reoccurrence is unknown. Therefore, we aimed to quantify MI's stress and financial burden after surviving cancer and compare to those never diagnosed with cancer. Utilizing cross-sectional national survey data from 2013 to 2018 derived from publicly available United States datasets, the National Health Interview Survey , and economic data from the National Inpatient Sample , we compared the socio-economic outcomes in those with MI by cancer-status. We adjusted for social, demographic, and clinical factors. Overall, 19,504 (10.2%) of the 189,836 National Health Interview Survey responders reported having cancer for more than 1 year. There was an increased prevalence of MI in cancer survivors compared with noncancer patients (8.8% vs 3.2%, p <0.001). MI was associated with increased financial worry, food insecurity, and financial burden of medical bills (p <0.001, respectively); however, concurrent cancer did not seem to be an effect modifier (p >0.05). There was no difference in annual residual family income by cancer status; however, 3 lowest deciles of residual income representing 21.1% cancer-survivor with MI had a residual income of <$9,000. MI continues to represent an immense source of financial and perceived stress. In conclusion, although cancer patients face a higher risk of subsequent MI, this does not appear to advance their reported stress significantly.

Identifiants

pubmed: 33217349
pii: S0002-9149(20)31229-7
doi: 10.1016/j.amjcard.2020.11.005
pmc: PMC8406452
mid: NIHMS1649077
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-22

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001864
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA133250
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Am Soc Clin Oncol Educ Book. 2017;37:35-39
pubmed: 28561659
Fed Regist. 2018 Apr 17;83(74):16930-7070
pubmed: 30015469
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Clin Genitourin Cancer. 2016 Feb;14(1):28-37.e2
pubmed: 26382223
Med Care. 2018 Mar;56(3):220-227
pubmed: 29438192
J Natl Compr Canc Netw. 2018 Oct;16(10):1216-1247
pubmed: 30323092
J Natl Med Assoc. 2011 Aug;103(8):729-34
pubmed: 22046850
Circulation. 2019 Mar 26;139(13):e579-e602
pubmed: 30786722
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
Support Care Cancer. 2018 Apr;26(4):1265-1272
pubmed: 29105024
J Am Coll Cardiol. 2020 Feb 18;75(6):620-628
pubmed: 32057377
N Engl J Med. 2013 Mar 14;368(11):1055-6
pubmed: 23484833
Circulation. 2019 Feb 26;139(9):e44-e54
pubmed: 30674212
J Am Coll Cardiol. 2019 Feb 19;73(6):727-732
pubmed: 30765039
Cancer. 2019 May 15;125(10):1737-1747
pubmed: 30663039
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Lancet. 2019 Sep 21;394(10203):1041-1054
pubmed: 31443926
Cancer. 2013 Jun 1;119 Suppl 11:2187-99
pubmed: 23695931
ESC Heart Fail. 2019 Aug;6(4):733-746
pubmed: 31264809

Auteurs

Avirup Guha (A)

Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio.

Amit Kumar Dey (AK)

National Heart, Lung and Blood Institute, Bethesda, Maryland.

Sadeer Al-Kindi (S)

Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio.

P Elliott Miller (PE)

Division of Cardiology, Yale University School of Medicine, New Haven, Connecticut; Yale National Clinician Scholars Program, New Haven, Connecticut.

Arjun K Ghosh (AK)

Cardio-Oncology Service, Bart's Heart Centre and University College London Hospital, Hatter Cardiovascular Institute, London, United Kingdom.

Amitava Banerjee (A)

Institute of Health Informatics, University College London, London, United Kingdom.

Juan Lopez-Mattei (J)

Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Nihar R Desai (NR)

Division of Cardiology, Yale University School of Medicine, New Haven, Connecticut; Center for Outcomes Research and Evaluation, New Haven, Connecticut.

Brijesh Patel (B)

Division of Cardiology, West Virginia University, Morgantown, West Virginia.

Guilherme H Oliveira (GH)

Cardio-Oncology Program, Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine and H. Lee Moffitt Cancer Center and Research Institute and, Tampa, Florida.

Marcos de Lima (M)

Adult Hematologic Malignancies and Stem Cell Transplant Program, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

Michael Fradley (M)

Cardio-Oncology Program, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennysylvania.

Daniel Addison (D)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio; Cancer Control Program, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio. Electronic address: daniel.addison@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH